Details for Patent: 7,452,857
✉ Email this page to a colleague
Title: | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
Abstract: | Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease. |
Inventor(s): | Lin; Henry C. (Manhattan Beach, CA), Pimentel; Mark (Los Angeles, CA) |
Assignee: | Cedars-Sinai Medical Center (Los Angeles, CA) |
Filing Date: | Sep 23, 2005 |
Application Number: | 11/234,516 |
Claims: | 1. A method of treating irritable bowel syndrome in a subject, comprising: providing a composition comprising rifaximin; and administering the composition to the subject in an amount sufficient to at least partially eradicate small intestinal bacterial overgrowth in the subject, whereby the irritable bowel syndrome is treated. 2. The method of claim 1, wherein treatment of irritable bowel syndrome comprises an improvement in a symptom associated with irritable bowel syndrome selected from the group consisting of diarrhea, bloating, constipation, abdominal pain, and combinations thereof. 3. The method of claim 1, wherein the rifaximin is administered orally. 4. The method of claim 1, wherein the composition comprises a unitized amount of rifaximin. 5. The method of claim 1, wherein the rifaximin is dehydrated rifaximin. 6. The method of claim 1, where in the rifaximin is lyophilized rifaximin. 7. The method of claim 1, wherein the administering results in an improvement of irritable bowel syndrome based on visual analog scores. 8. The method of claim 1, wherein the administering results in improvement of extraintestinal symptoms of irritable bowel syndrome. 9. The method of claim 8, wherein the extraintestinal symptoms include joint pain and fatigue. 10. The method of claim 1, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth. 11. The method of claim 1, wherein the administering results in greater than 90% improvement in symptoms of irritable bowel syndrome. 12. A method of treating irritable bowel syndrome in a human subject, comprising: providing a composition comprising rifaximin; and administering the composition to the human subject, wherein the administering relieves symptoms of irritable bowel syndrome. 13. The method of claim 12, wherein the composition comprises a unitized amount of rifaximin. 14. The method of claim 12, wherein the rifaximin is dehydrated rifaximin. 15. The method of claim 12, where in the rifaximin is lyophilized rifaximin. 16. The method of claim 12, wherein the administering results in an improvement of irritable bowel syndrome based on visual analog scores. 17. The method of claim 12, wherein the administering results in improvement of extraintestinal symptoms of irritable bowel syndrome. 18. The method of claim 17, wherein the extraintestinal symptoms include joint pain and fatigue. 19. The method of claim 12, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth. 20. The method of claim 12, wherein the administering results in greater than 90% improvement in symptoms of irritable bowel syndrome. 21. The method of claim 12, wherein the rifaximin is administered orally. |